FairValu
BOSTON SCIENTIFIC CORP

BOSTON SCIENTIFIC CORP

BSXNYSE

Medical Devices • Healthcare

Current Price
$46.840.00%
Market Cap
$67.88B
Shares Outstanding: 1.45B
Volume
-
Avg Vol (3M): -
Next Earnings
-
52 Week Range
Low: $--High: $--

Comprehensive AI Analysis

Strategic AI Analysis for BSX

Checking whether the approved providers contain enough current financial data for a reliable report.

Summary

Source-linked company research for BSX

Factor Scorecard

Mechanical 0-100 composites from the displayed inputs. Bands and colours are numerical aids, not security ratings or investment actions.

24/31 signals active· low confidence at 77% coverage
Overall Factor Score
7270-84 band
Growth
6255-69 band
Quality
8170-84 band
Valuation
7670-84 band
Financial Health
6855-69 band

Latest results at a glance

Insights from the latest company results and reports

  • Quarterly Earnings Exceed Consensus

    Reported EPS of $0.86 per share exceeded the same-quarter consensus estimate of $0.83 per share for the period ended 2026-06-30.

  • Revenue Growth Accelerates

    Revenue for the quarter ended 2026-06-30 was $5.44bn, up 7.53% from $5.06bn for the quarter ended 2025-06-30.

  • Net Income Rises Year-Over-Year

    Net income for the quarter ended 2026-06-30 was $905.0m, up 13.84% from $795.0m for the quarter ended 2025-06-30.

  • Gross Margin Expands

    Gross margin for the quarter ended 2026-06-30 was 70.71%, wider than the 67.65% recorded for the quarter ended 2025-06-30.

  • Electrophysiology Segment Leads Growth

    Electrophysiology EP revenue of $2.31bn was 11.5% of consolidated revenue for the period ended 2025-12-31, up 84.0% from $1.26bn in 2024-12-31.

AI-generated · updated 27 Aug 2026

Price Chart

NYSE:BSX via TradingView

Loading TradingView chart...

Overview

Quarterly income statement data isn't available for this company.

No Data

No annual financial data available.

Financial Fundamentals

Growth, quality, valuation, cash generation, and balance-sheet strength.

Sector: Healthcare

Growth

TTM revenue plus current, long-term, forward, and accelerating top-line trends.

Revenue
-
Revenue Growth
13.5%
Moderate
Revenue CAGR 3Y
-
Forward Revenue Growth
6.4%
Moderate
Revenue Acceleration
-7.9%
Slowing

Earnings

Trailing EPS, current EPS growth, long-term compounding, surprise, and forward expectations.

EPS (TTM)
2.53
Profitable
EPS Growth
46.9%
Excellent
EPS CAGR 3Y
-
EPS Surprise
3.9%
Beat
Forward EPS
3.30
Profitable
Fwd Revenue Growth
6.4%
Forward EPS Growth
3.9%
Weak

Profitability

TTM margin and return metrics that reflect pricing power and business quality.

Gross Margin
69.9%
High
Operating Margin
19.8%
High
Net Margin
17.5%
High
ROE
14.7%
Good
ROIC
15.1%
Strong

Cash Flow

TTM free cash flow, growth, margin, and operating-cash conversion quality.

Free Cash Flow
$3.63B
Positive
FCF Growth
4.0%
Weak
FCF Margin
-
Cash Conversion
1.23x
Excellent

Valuation

Metrics ranked by issuer type, financial state, and input quality.

Established companyPrimary lens

Forward P/E

Forward P/E is the primary lens because positive expected earnings make the next operating period directly assessable.

Forward P/EPrimary
14.18x
Low
EV / EBITDASupporting
11.93x
Typical
EV / FCFSupporting
19.05x
Typical
Trailing P/ESupporting
18.50x
Typical

Financial Health

Latest-quarter liquidity and leverage checks plus TTM interest coverage.

Current Ratio
1.24x
Adequate
Quick Ratio
0.08x
Risky
Debt / Equity
0.07x
Conservative
Interest Coverage
11.44x
Safe

Shareholder Signals

Capital returns and dilution checks sourced from statements and insider filings.

Net Insider Buys
+10
Buying

Peer Comparison

TickerPrice
BSXBOSTON SCIENTIFIC CORP
$46.84
Company Profile

About the Company

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. The company operates in two segments, MedSurg and Cardiovascular. It offers devices to diagnose and treat a range of gastrointestinal conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, SpyGlass, single-use scopes used for diagnostic and therapeutic procedures in the pancreaticobiliary system, in endoscopic retrograde cholangiopancreatography procedures, and single-use duodenoscopes, as well as endoluminal surgery and infection prevention products; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, urinary and bowel dysfunction, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, penile implants, artificial urinary sphincter, laser system, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator systems, radiofrequency ablation, and intraosseous nerve ablation and deep brain stimulation systems. The company also provides technologies for diagnosing and treating a range of diseases and abnormalities of the heart; WATCHMAN FLX, a left atrial appendage closure (LAAC) device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems. In addition, it offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose and treat forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.

Next Earnings Date

Oct 28, 2026

Loading latest news...

BOSTON SCIENTIFIC CORP (BSX) AI Stock Summary